Trial Profile
The prognostic significance of e13a2 and b14a2 BCR/ABL1 transcripts in chronic myeloid leukaemia patients who switched to nilotinib after suboptimal response or failure on frontline imatinib therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Jul 2017
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Biomarker; Pharmacodynamics
- 24 Jul 2017 New trial record
- 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association